CROSS-FILE REVIEW
Four compounds, four documentation burdens
A side-by-side clinical brief on what is studied, how mature the evidence is, and which link in the supply-documentation chain deserves the closest inspection.
In plain English
These four peptides do not form a treatment ladder. They belong together because they expose different documentation problems. GHK-Cu shows why chemical form and delivery matter. Tesamorelin shows why an approved product context cannot be reduced to a peptide name. KPV shows that excellent material documentation cannot create missing human evidence. Retatrutide shows why promising trial results do not authenticate uncontrolled material.
The first comparison is therefore not which compound is “best.” It is which question the evidence can answer. GHK-Cu has topical, ex vivo, cell, and review evidence. Tesamorelin has randomized human trials in a defined HIV-associated condition. KPV has a coherent preclinical gut-inflammation program but no human trial in this corpus. Retatrutide has substantial Phase 2 human findings and remains investigational.
A specification defines intended attributes. A certificate reports results. Custody connects the sample to the lot. Independent assays test particular claims. Clinical literature then answers a separate question: what happened under studied conditions. A defensible conclusion requires all of those layers to stay distinct.
The comparison matrix
| File | Core mechanism | Evidence maturity | Studied focus | Documentation priority |
|---|---|---|---|---|
| GHK-Cu | Copper chaperoning and distributed repair signaling [2][6] | Cell, ex vivo skin, reviews, small topical human studies [1][3][5] | Skin delivery, matrix synthesis, hair and repair signals | Confirm copper-bound form; separate identity, copper content, complex integrity, and delivery |
| Tesamorelin | Pituitary GHRH receptor agonism, raising endogenous GH and IGF-1 [11] | Randomized human trials and approved-use safety literature [8][9][10][12] | HIV-associated visceral adiposity and related liver-fat outcomes | Separate regulated product provenance from research-grade identity claims |
| KPV | PepT1 uptake with reduced NF-kB and MAP-kinase inflammatory signaling [15] | Cell and animal studies [13][14][16][17] | Experimental intestinal inflammation and targeted delivery | Keep formulation-specific results and preclinical status explicit |
| Retatrutide | GIP, GLP-1, and glucagon receptor agonism [19] | Phase 2 human trials; later-stage questions ongoing [20][21][22] | Obesity, type 2 diabetes, and metabolic liver fat | Verify provenance and lot linkage; do not transfer trial results to unverified material |
Evidence maturity is not a purity score
GHK-Cu and KPV illustrate the point from opposite directions. GHK-Cu has broad mechanistic literature and some human topical signals, but native skin penetration is limited and formulation changes exposure [1][5]. KPV has consistent cell and mouse findings involving inflammatory pathways and colon-targeted delivery [13][14][15][16], yet the human clinical column remains blank. A chemically pure sample of either compound would not upgrade the evidence level.
Tesamorelin and retatrutide both have controlled human data, but their regulatory positions differ. Tesamorelin's approval is tied to a specific HIV-associated indication [9]. Retatrutide's large Phase 2 signals remain part of an investigational program [18][21][22]. “Human data” is therefore not one category. Trial phase, population, comparator, endpoint, product control, and follow-up all determine what can be concluded.
What each document can establish
Specification: the intended identity, form, and acceptance criteria. It should be written before results are interpreted. For GHK-Cu, copper coordination belongs in the identity question. For KPV, the short sequence and formulation need clear separation. For engineered analogues, modifications matter.
Certificate: reported results for a named lot. Method names, laboratory identity, dates, acceptance limits, and traceable sample identifiers make it useful. A template detached from a batch does not.
Custody record: the path between sampling, transfer, storage, testing, and the represented inventory. It answers whether the assay result can be connected to the material under discussion.
Independent assay: a measurement conducted outside the seller's own release process. Independence reduces one conflict but does not make the method comprehensive. Identity, purity, concentration, water, residual solvent, sterility, and endotoxin require different methods and may not all apply to every research context.
Published literature: evidence about a characterized material under stated experimental conditions. It can show a mechanism or outcome. It cannot validate an unknown sample.
Cross-file findings
The compound-level conclusions are concise. GHK-Cu has plausible tissue-remodeling biology with topical formulation constraints and limited controlled human breadth [1][2][3][4][5][6][7]. Tesamorelin has the strongest approved-use context and shows visceral-fat reduction in adults with HIV-associated lipodystrophy, with effects that can reverse after discontinuation [8][9][10][12]. KPV remains a preclinical anti-inflammatory and delivery research story [13][14][15][16][17]. Retatrutide has the largest recent Phase 2 metabolic signals but unresolved long-term outcomes and no approval [18][20][21][22].
The common rule is stricter than a marketing claim and simpler than a laboratory report: match the result to the material, the material to the lot, the lot to the custody record, and the biological claim to the exact evidence tier. Anything less leaves a broken link.